文献速递脑血管病外科神经重症

动脉瘤性蛛网膜下腔出血患者静脉血栓栓塞症的发生率与风险模型

Incidence and Risk Model of Venous Thromboembolism in Patients with Aneurysmal Subarachnoid Hemorrhage.
PubMed 文献 · World Neurosurg · 2023-01-16

该回顾性队列研究纳入2014至2018年收治的485例动脉瘤性蛛网膜下腔出血患者,静脉血栓栓塞症总体发生率为5.6%,深静脉血栓为4.3%,肺栓塞为2.3%。重症监护室住院时间延长和动脉瘤治疗后立即机械通气与静脉血栓栓塞症相关,调整后4年累积发生率为11.1%。作者建议针对该人群制定标准化的筛查、预防和治疗方案。

要点

  • 485例aSAH患者中VTE总体发生率为5.6%,DVT为4.3%,PE为2.3%。
  • ICU住院时间延长(HR 1.79)和动脉瘤治疗后立即通气(HR 8.87)与VTE相关。
  • 调整后4年VTE累积发生率为11.1%,出院时平均为5.4%。

核心结论

  • 作者报告了目前最大的单中心aSAH患者VTE队列,其风险模型量化了住院期间VTE的累积发生率,并建议对该人群制定标准化的VTE筛查、预防和治疗方案。

研究设计与样本

  • 回顾性队列研究,纳入2014至2018年收治的485例动脉瘤性蛛网膜下腔出血患者,基于临床怀疑进行VTE筛查,采用以死亡为竞争风险的生存分析评估VTE危险因素。

主要发现

  • 485例患者中VTE、深静脉血栓和肺栓塞的总体发生率分别为5.6%、4.3%和2.3%。
  • 重症监护室住院时间延长与VTE相关(HR 1.79;P < 0.0001;95%CI 1.49-2.16)。
  • 动脉瘤治疗后立即通气与VTE相关(HR 8.87;P < 0.01;95%CI 1.86-42.38)。
  • Hunt和Hess分级与VTE呈负相关(HR 0.61;P = 0.045;95%CI 0.37-1.00),因其与竞争风险死亡的相关性增加(HR 2.57;P < 0.0001;95%CI 1.89-3.49)。
  • 调整后4年VTE累积发生率为11.1%,住院出院平均日VTE累积发生率为5.4%。

关键数值与推荐

  • VTE总体发生率5.6%,深静脉血栓4.3%,肺栓塞2.3%(485例aSAH患者)。
  • ICU住院时间延长:HR 1.79(P < 0.0001;95%CI 1.49-2.16)。
  • 动脉瘤治疗后立即通气:HR 8.87(P < 0.01;95%CI 1.86-42.38)。
  • Hunt和Hess分级与VTE负相关:HR 0.61(P = 0.045;95%CI 0.37-1.00);与死亡竞争风险正相关:HR 2.57(P < 0.0001;95%CI 1.89-3.49)。
  • 调整后4年VTE累积发生率11.1%,出院平均日5.4%。

临床怎么用

  • 作者建议针对aSAH患者制定标准化的VTE筛查、预防和治疗方案。
  • 使用抗凝和/或下腔静脉滤器治疗VTE与即时并发症无关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Venous thromboembolism (VTE) is a significant source of morbidity and mortality in hospitalized patients. We describe our experience with VTE prophylaxis and treatment in patients with aneurysmal subarachnoid hemorrhage (aSAH), risk factors for VTE, and a hazard model describing the daily risk of VTE. METHODS: A retrospective cohort study was performed on patients with aSAH admitted from 2014 to 2018. Patients were screened for VTE based on clinical suspicion. Demographics, perioperative data, and in-hospital data were assessed as risk factors for VTE using survival analysis with death as a competing risk. RESULTS: Among 485 patients, the overall incidence of VTE, deep vein thrombosis, and pulmonary embolism were 5.6%, 4.3%, and 2.3%, respectively. Increasing length of stay in the intensive care unit (hazard ratio [HR], 1.79; P < 0.0001; 95% confidence interval [CI], 1.49-2.16) and ventilation immediately after aneurysm treatment was associated with VTE (HR, 8.87; P < 0.01; 95% CI, 1.86-42.38). Hunt and Hess grade was negatively associated with VTE (HR, 0.61; P = 0.045; 95% CI, 0.37-1.00) due to its increased association with the competing risk of death (HR, 2.57; P < 0.0001; 95% CI, 1.89-3.49). The adjusted 4-year cumulative incidence for VTE is 11.1% and at mean day of hospital discharge is 5.4%. Treatment of VTEs with anticoagulation and/or inferior vena cava filter placement was not associated with immediate complications. CONCLUSIONS: We describe the largest single-institution cohort of VTEs in aSAH patients. Our hazard model quantifies the cumulative incidence of VTEs during the course of hospitalization. We suggest a standardized protocol for screening, prophylaxis, and treatment of VTEs in this patient population.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Pan J, Bonow RH, Temkin N, et al. Incidence and Risk Model of Venous Thromboembolism in Patients with Aneurysmal Subarachnoid Hemorrhage. World Neurosurg. 2023. PMID: 36657716. doi:10.1016/j.wneu.2023.01.045

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。